When selecting the appropriate formulation of Livmarli, the patient's weight and ability to swallow tablets should be considered. Livmarli tablets are supplied in 10mg, 15mg, 20mg, and 30mg dosage ...
FOSTER CITY, Calif., April 14, 2025--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has approved a new tablet formulation ...
13-Week Study to Evaluate the Safety and Efficacy of Oral VK2735 Dosed Once Daily SAN DIEGO, Jan. 8, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage ...
Validating the match between the active ingredient content mentioned in the packaging and the actual content in each tablet in a batch is a critical step in tablet manufacture. Highly precise ...
The Food and Drug Administration initially approved the chewable tablet formulation in January 2017. Vyvanse (lisdexamfetamine dimesylate; Shire) is now available as chewable tablets for the treatment ...
Roche has announced that a tablet formulation of its spinal muscular atrophy (SMA) treatment Evrysdi (risdiplam) has been approved by the US Food and Drug Administration (FDA). Evrysdi was originally ...
To evaluate and compare patient tolerability, acceptance and preference of bowel preparation with sodium phosphate tablets with that of polyethylene glycol (PEG) solution plus bisacodyl tablets for ...
Objective: To compare the 24-hour sustained efficacy and safety of a new tramadol once-daily formulation (tramadol OAD) using Contramid ® controlled-release technology with a marketed twice-daily ...
This unique 3 day course is designed to integrate the key elements of tablet development with hands-on, practical experience in a small scale, lab scale test facility. Each day will consist of ...
This optional practical day follows the 2 day course ' Tablet Formulation Development ' which introduces and integrates the key elements of tablet development with the principles of Quality by Design ...
Background: NSAIDs are widely used for patients presenting with low back pain. A quick-release formulation of lornoxicam, a potent NSAID from the chemical class of oxicams, offers a faster onset of ...
The European Medicines Agency’s human medicines committee has recommended approval of a new tablet formulation of BeOne Medicines’ targeted blood cancer drug Brukinsa (zanubrutinib). The company ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback